Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate

NCT04351191 is registered in ClinicalTrials.gov with Government of Punjab, Specialized Healthcare and Medical Education Department as lead sponsor.

NCT NCT04351191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04351191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
Lead sponsor
Government of Punjab, Specialized Healthcare and Medical Education Department
Phase
Phase 4
Overall status
Terminated
Start date
April 15, 2020
Completion date
August 30, 2020
Enrollment
137 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov2, symptomatic condition